ADVM שווי כולל של נכסי החברה Adverum

This chart of Adverum Biotechnologies (ADVM) total asset value on the GURU.Markets platform is 153.39. The company currently operates without profitable products, relying on investments to cover operating expenses. Future revenue growth is expected from the implementation of Ixo-vec for the therapy of macular degeneration. Meanwhile, the success of the treatment depends on a strict temperature regime during the transportation of drugs to specialized centers.

Complex patent barriers and capital-intensive FDA trials in the gene therapy sector drive the high resource costs of Adverum Biotechnologies (ADVM). The company's current asset level, calculated reverse-engineered through return on assets (ROA), reflects the aggregate of equity and liabilities, allowing investors to assess the scale of the material base and the financial stability of the business during the development of high-cost drugs.